Unfavorable-risk cytogenetics in acute myeloid leukemia

References

• Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev.18(2), 115–136 (2004).
   PubMed Web of Science ®Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood96(13), 4075–4083 (2000).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrozek K, Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood100(13), 4325–4336 (2002).
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood116(3), 354–365 (2010).
   PubMed Web of Science ®Google Scholar
• Mrozek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin. Oncol.35(4), 365–377 (2008).
   PubMed Web of Science ®Google Scholar
• Farag SS, Archer KJ, Mrozek K et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood108(1), 63–73 (2006).
   PubMed Web of Science ®Google Scholar
• Lancet JE, Giralt S. Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant. J. Natl Compr. Canc. Netw.6(10), 1017–1025 (2008).
   PubMedGoogle Scholar
• Shaffer LG, Slovak ML, Campbell LJ; International Standing Committee on Human Cytogenetic Nomenclature. ISCN 2009: An International System for Human Cytogenetic Nomenclature. Karger, Basel, Switzerland (2009).
   Google Scholar
• Mrozek K, Carroll AJ, Maharry K et al. Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int. J. Oncol.33(2), 239–244 (2008).
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood92(7), 2322–2333 (1998).
   PubMed Web of Science ®Google Scholar
• Breems DA, Van Putten WL, De Greef GE et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J. Clin. Oncol.26(29), 4791–4797 (2008).
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood116(13), 2224–2228 (2010).
   PubMed Web of Science ®Google Scholar
• Stone RM, Berg DT, George SL et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N. Engl. J. Med.332(25), 1671–1677 (1995).
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood107(9), 3481–3485 (2006).
   PubMed Web of Science ®Google Scholar
• Bloomfield CD, Goldman A, Hossfeld D, de la Chapelle A. Fourth International Workshop on Chromosomes in Leukemia 1982: clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet. Cytogenet.11(3), 332–350 (1984).
   PubMedGoogle Scholar
• Arthur DC, Berger R, Golomb HM et al. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet. Cytogenet.40(2), 203–216 (1989).
   PubMed Web of Science ®Google Scholar
• Swansbury GJ, Lawler SD, Alimena G et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet. Cytogenet.73(1), 1–7 (1994).
   PubMed Web of Science ®Google Scholar
• Bloomfield CD, Shuma C, Regal L et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer80(11 Suppl.), 2191–2198 (1997).
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Kayser S et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood108(10), 3280–3288 (2006).
   PubMed Web of Science ®Google Scholar
• van der Holt B, Breems DA, Berna Beverloo H et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. Br. J. Haematol.136(1), 96–105 (2007).
   PubMed Web of Science ®Google Scholar
• Wheatley K, Brookes CL, Howman AJ et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br. J. Haematol.145(5), 598–605 (2009).
   PubMed Web of Science ®Google Scholar
• Rollig C, Thiede C, Gramatzki M et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood116(6), 971–978 (2010).
   PubMed Web of Science ®Google Scholar
• Krug U, Rollig C, Koschmieder A et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet376(9757), 2000–2008 (2010).
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Elson P, Kalaycio ME et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood113(1), 28–36 (2009).
   PubMed Web of Science ®Google Scholar
• Kiss TL, Sabry W, Lazarus HM, Lipton JH. Blood and marrow transplantation in elderly acute myeloid leukaemia patients – older certainly is not better. Bone Marrow Transplant.40(5), 405–416 (2007).
   PubMed Web of Science ®Google Scholar
• Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood89(9), 3323–3329 (1997).
   PubMed Web of Science ®Google Scholar
• Leith CP, Kopecky KJ, Chen IM et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood94(3), 1086–1099 (1999).
   PubMed Web of Science ®Google Scholar
• Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood104(7), 1940–1951 (2004).
   PubMed Web of Science ®Google Scholar
• Cripe LD, Uno H, Paietta EM et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood116(20), 4077–4085 (2010).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Erba HP, Claxton D et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J. Clin. Oncol.28(4), 549–555 (2010).
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Kell J et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J. Clin. Oncol.28(14), 2389–2395 (2010).
   PubMed Web of Science ®Google Scholar
• Schiller GJ, O’Brien SM, Pigneux A et al. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J. Clin. Oncol.28(5), 815–821 (2010).
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer103(8), 1652–1658 (2005).
   PubMed Web of Science ®Google Scholar
• Koreth J, Schlenk R, Kopecky KJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA301(22), 2349–2361 (2009).
   PubMed Web of Science ®Google Scholar
• Gupta V, Tallman MS, He W et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood116(11), 1839–1848 (2010).
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Döhner K, Mack S et al. Prospective evaluation of allogeneic hematopoietic stem cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German–Austrian trial AMLHD98A. J. Clin. Oncol.28(30), 4642–4648 (2010).
   PubMed Web of Science ®Google Scholar
• Aoudjhane M, Labopin M, Gorin NC et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia19(12), 2304–2312 (2005).
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon, France (2008).
   Google Scholar
• Ageberg M, Drott K, Olofsson T, Gullberg U, Lindmark A. Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis. Genes Chromosomes Cancer47(4), 276–287 (2008).
   PubMedGoogle Scholar
• Slovak ML, Gundacker H, Bloomfield CD et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies. Leukemia20(7), 1295–1297 (2006).
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood99(12), 4326–4335 (2002).
   PubMed Web of Science ®Google Scholar
• Groschel S, Lugthart S, Schlenk RF et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J. Clin. Oncol.28(12), 2101–2107 (2010).
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Kohrt HE, Arber DA et al. Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Leuk. Res.34(5), 594–597 (2010).
   PubMed Web of Science ®Google Scholar
• Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood101(3), 837–845 (2003).
   PubMed Web of Science ®Google Scholar
• Lugthart S, Groschel S, Beverloo HB et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J. Clin. Oncol.28(24), 3890–3898 (2010).
   PubMed Web of Science ®Google Scholar
• Cuneo A, Ferrant A, Michaux JL et al. Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Haematologica81(5), 423–427 (1996).
   PubMed Web of Science ®Google Scholar
• Paietta E, Racevskis J, Bennett JM et al. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia12(12), 1881–1885 (1998).
   PubMed Web of Science ®Google Scholar
• Keung YK, Beaty M, Powell BL, Molnar I, Buss D, Pettenati M. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk. Res.28(6), 579–586 (2004).
   PubMed Web of Science ®Google Scholar
• Soupir CP, Vergilio JA, Dal Cin P et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am. J. Clin. Pathol.127(4), 642–650 (2007).
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Kopecky KJ, Meshinchi S et al.FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood97(11), 3589–3595 (2001).
   PubMed Web of Science ®Google Scholar
• Seifert H, Mohr B, Thiede C et al. The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia23(4), 656–663 (2009).
   PubMed Web of Science ®Google Scholar
• Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J. Clin. Oncol.19(5), 1405–1413 (2001).
   PubMed Web of Science ®Google Scholar
• Nahi H, Lehmann S, Bengtzen S et al. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leuk. Lymphoma49(3), 508–516 (2008).
   PubMed Web of Science ®Google Scholar
• Nahi H, Merup M, Lehmann S et al. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br. J. Haematol.132(2), 230–236 (2006).
   PubMed Web of Science ®Google Scholar
• Nahi H, Selivanova G, Lehmann S et al. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br. J. Haematol.141(4), 445–453 (2008).
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia22(2), 240–248 (2008).
   PubMed Web of Science ®Google Scholar
• Liu TX, Becker MW, Jelinek J et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation. Nat. Med.13(1), 78–83 (2007).
   PubMed Web of Science ®Google Scholar
• Ebert BL, Pretz J, Bosco J et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature451(7176), 335–339 (2008).
   PubMed Web of Science ®Google Scholar
• Peng J, Kitchen SM, West RA, Sigler R, Eisenmann KM, Alberts AS. Myeloproliferative defects following targeting of the Drf1 gene encoding the mammalian diaphanous related formin mDia1. Cancer Res.67(16), 7565–7571 (2007).
   PubMed Web of Science ®Google Scholar
• Eisenmann KM, Dykema KJ, Matheson SF et al. 5q-myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene28(39), 3429–3441 (2009).
   PubMed Web of Science ®Google Scholar
• Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood104(5), 1474–1481 (2004).
   PubMed Web of Science ®Google Scholar
• Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia17(9), 1813–1819 (2003).
   PubMed Web of Science ®Google Scholar
• Au WY, Fung A, Man C et al. Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. Br. J. Haematol.120(6), 1062–1065 (2003).
   PubMed Web of Science ®Google Scholar
• Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer43(3), 227–238 (2005).
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood98(5), 1312–1320 (2001).
   PubMed Web of Science ®Google Scholar
• Rucker FG, Bullinger L, Schwaenen C et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J. Clin. Oncol.24(24), 3887–3894 (2006).
   PubMed Web of Science ®Google Scholar
• Mrozek K, Heinonen K, Theil KS, Bloomfield CD. Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q. Genes Chromosomes Cancer34(2), 137–153 (2002).
   PubMed Web of Science ®Google Scholar
• Van Limbergen H, Poppe B, Michaux L et al. Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH. Genes Chromosomes Cancer33(1), 60–72 (2002).
   PubMed Web of Science ®Google Scholar
• Schoch C, Haferlach T, Bursch S et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer35(1), 20–29 (2002).
   PubMed Web of Science ®Google Scholar
• Le DT, Kong N, Zhu Y et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood103(11), 4243–4250 (2004).
   PubMed Web of Science ®Google Scholar
• Bollag G, Clapp DW, Shih S et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet.12(2), 144–148 (1996).
   PubMed Web of Science ®Google Scholar
• Baldus CD, Liyanarachchi S, Mrozek K et al. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: amplification discloses overexpression of APP, ETS2, and ERG genes. Proc. Natl Acad. Sci. USA101(11), 3915–3920 (2004).
   PubMed Web of Science ®Google Scholar
• Marcucci G, Baldus CD, Ruppert AS et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J. Clin. Oncol.23(36), 9234–9242 (2005).
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry K, Whitman SP et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J. Clin. Oncol.25(22), 3337–3343 (2007).
   PubMed Web of Science ®Google Scholar
• Poppe B, Vandesompele J, Schoch C et al. Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood103(1), 229–235 (2004).
   PubMed Web of Science ®Google Scholar
• Zatkova A, Schoch C, Speleman F et al. GAB2 is a novel target of 11q amplification in AML/MDS. Genes Chromosomes Cancer45(9), 798–807 (2006).
   PubMed Web of Science ®Google Scholar
• Storlazzi CT, Fioretos T, Surace C et al. MYC-containing double minutes in hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as the target gene. Hum. Mol. Genet.15(6), 933–942 (2006).
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood115(3), 453–474 (2010).
   PubMed Web of Science ®Google Scholar